UniQure stock soars on early-stage trial results for Huntington’s disease

The company said interim data from the Phase 1/2 trials of its gene therapy, AMT-130, showed it slowed disease progression in Huntington’s disease.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks